What is the objective of the Investor Year of Action on AMR?
The objective of this year-long initiative is to align the behaviour of investors and the broader financial community to international standards, goals and guidelines, such as the Sustainable Development Goals, the Political Declaration of the High-Level Meeting of the General Assembly on Antimicrobial Resistance, the United Nations Inter-Agency Coordination Group on Antimicrobial Resistance's (IACG) final recommendations and the WHO Global Action Plan on Antimicrobial Resistance. Investors will be encouraged to assess and integrate risks, opportunities and impacts related to antimicrobial resistance (applying an antimicrobial resistance and One Health "lens") when making investment decisions and engaging with investee companies.
When will the Investor Year of Action on AMR be announced?
The group announced the Investor Year of Action on AMR at an Affiliated session of the World Economic Forum Annual Meeting, in Davos-Klosters, Swtizerland. The session was the launch event of the 2020 AMR Benchmark, was hosted by the Access to Medicine Foundation and took place on Thursday 23 January from 8:45 to 10 AM in Dome E of the Ice Village at Davos.
What does the Investor Year of Action on AMR entail?
The Investor Year of Action on AMR will run in 2020 and will be supported by a range of activities including, but not limited to, the following:
- Events and webinars on AMR
- Inclusion of AMR as a discussion topic at institutional investor conferences
- Media articles and op-eds across global markets
- Research reports
- Public individual investor commitments on AMR